MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/190/0.1/17.01.25 Stock

Warrant

DE000ME9ZMR6

Real-time Bid/Ask 09:35:26 2024-07-01 EDT
0.3 EUR / 0.31 EUR +1.67% Intraday chart for MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/190/0.1/17.01.25
Current month+48.51%
1 month+53.85%
Date Price Change
24-07-01 0.26 -13.33%
24-06-28 0.3 -3.23%
24-06-27 0.31 -3.13%
24-06-26 0.32 -11.11%
24-06-25 0.36 +33.33%

Delayed Quote Börse Stuttgart

Last update July 01, 2024 at 09:19 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME9ZMR
ISINDE000ME9ZMR6
Date issued 2024-03-11
Strike 190 $
Maturity 2025-01-17 (200 Days)
Parity 10 : 1
Emission price 0.6
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.47
Lowest since issue 0.154
Delta0x
Omega 0.000000
Premium0x
Gearing0x
Moneyness 0.7513
Difference Strike 45.57 $
Difference Strike %+23.98%
Theoretical value 0.3050
Implied Volatility 33.42 %
Total Loss Probability 87.13 %
Intrinsic value 0.000000
Present value 0.3050
Break even 193.28 €
Theta-0.02x
Vega0.03x
Rho0.01x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006 DKK
Average target price
949.7 DKK
Spread / Average Target
-5.56%
Consensus